Drug Profile

710 GO

Alternative Names: 710-GO

Latest Information Update: 08 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Endevica Bio
Class Obesity therapies; Peptides
Mechanism of Action Melanocortin type 3 receptor agonists; Melanocortin type 4 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Obesity

Most Recent Events

25 Mar 2026 Pharmacodynamics and adverse events data from a preclinical study in Obesity released by Kalohexis
19 Mar 2026 Endevica Bio plans a first-in-human, randomised, placebo-controlled phase I clinical trial of 710 GO in healthy overweight and obese volunteers in the first half of 2026
02 Oct 2025 Adverse events and pharmacodynamics data from a preclinical trial in Obesity released by Endevica Bio

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com